Viral Vectors Plasmid Dna Manufacturing Market Viral Vectors Plasmid Dna Manufacturing Market : ToC


Viral Vectors Plasmid Dna Manufacturing Market

Viral Vector and Plasmid DNA Manufacturing Market (Type - Lentivirus, Adenovirus, Adeno-Associated Virus (AAV), Plasmid DNA; Application - Gene Therapy, Vaccinology; Disease - Genetic Disorders, Cancer, Infectious Disease; End user - Biotech Companies, Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • Rep Id : TMRGL30428
  • Published On : Apr 2019
  • No. of Pages : 199
  • Category : Healthcare

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Viral Vector & Plasmid DNA Manufacturing Market 

4. Market Overview
     4.1. Introduction
             4.1.1. Type Definition
             4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
             4.3.1. Drivers
             4.3.2. Restraints
             4.3.3. Opportunities
     4.4. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, 2017–2027
             4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1. Top 3 players operating in the market space
     5.2. Key Mergers & Acquisitions 
     5.2. List of Manufacturer by Location of Manufacturing Facility and Type of Vector Production

6. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027
             6.3.1. Retroviruses 
             6.3.2. Adenoviruses 
             6.3.3. Adeno-associated Viruses
             6.3.4. Plasmid DNA
             6.3.5. Others
     6.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type 

7. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Application 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027
             7.3.1. Gene Therapy 
             7.3.2. Vaccinology
             7.3.3. Others 
     7.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application 

8. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Disease 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027
             8.3.1. Genetic Disorders
             8.3.2. Cancer 
             8.3.3. Infectious Disease 
             8.3.4. Others
     8.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease 

9. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by End-user 
     9.1. Introduction & Definition
     9.2. Key Findings / Developments
     9.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027
             9.3.1. Biotech Companies
             9.3.2. Research Institutes
     9.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user 

10. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Region
     10.1. Key Findings
     10.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Region
             10.2.1. North America 
             10.2.2. Europe 
             10.2.3. Asia Pacific 
             10.2.4. Latin America 
             10.2.5. Middle East & Africa 
     10.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Region

11. North America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
     11.1. Introduction
             11.1.1. Key Findings
     11.2. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027
             11.2.1. Retroviruses 
             11.2.2. Adenoviruses 
             11.2.3. Adeno-associated Viruses
             11.2.4. Plasmid DNA
             11.2.5. Others
     11.3. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027
             11.3.1. Gene Therapy 
             11.3.2. Vaccinology
             11.3.3. Others 
     11.4. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027
             11.4.1. Genetic Disorders
             11.4.2. Cancer 
             11.4.3. Infectious Disease 
             11.4.4. Others
     11.5. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027
             11.5.1. Biotech Companies
             11.5.2. Research Institutes
     11.6. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country, 2017–2027
             11.6.1. U.S.
             11.6.2. Canada
     11.7. North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis 
             11.7.1. by Type 
             11.7.2. by Application 
             11.7.3. by Disease 
             11.7.4. by End-user 
             11.7.5. by Country

12. Europe Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
     12.1. Introduction
             12.1.1. Key Findings
     12.2. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027
             12.2.1. Retroviruses 
             12.2.2. Adenoviruses 
             12.2.3. Adeno-associated Viruses
             12.2.4. Plasmid DNA
             12.2.5. Others
     12.3. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027
             12.3.1. Gene Therapy 
             12.3.2. Vaccinology
             12.3.3. Others 
     12.4. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027
             12.4.1. Genetic Disorders
             12.4.2. Cancer 
             12.4.3. Infectious Disease 
             12.4.4. Others
     12.5. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027
             12.5.1. Biotech Companies
             12.5.2. Research Institutes
     12.6. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027
             12.6.1. Germany
             12.6.2. U.K.
             12.6.3. France
             12.6.4. Spain
             12.6.5. Italy
             12.6.6. Rest of Europe
     12.7. Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis 
             12.7.1. by Type 
             12.7.2. by Application 
             12.7.3. by Disease 
             12.7.4. by End-user 
             12.7.5. by Country/Sub-region

13. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
     13.1. Introduction
             13.1.1. Key Findings
     13.2. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027
             13.2.1. Retroviruses 
             13.2.2. Adenoviruses 
             13.2.3. Adeno-associated Viruses
             13.2.4. Plasmid DNA
             13.2.5. Others
     13.3. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027
             13.3.1. Gene Therapy 
             13.3.2. Vaccinology
             13.3.3. Others 
     13.4. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027
             13.4.1. Genetic Disorders
             13.4.2. Cancer 
             13.4.3. Infectious Disease 
             13.4.4. Others
     13.5. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027
             13.5.1. Biotech Companies
             13.5.2. Research Institutes
     13.6. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027
             13.6.1. China
             13.6.2. Japan
             13.6.3. India
             13.6.4. Australia & New Zealand
             13.6.5. Rest of Asia Pacific
     13.7. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis 
             13.7.1. by Type 
             13.7.2. by Application 
             13.7.3. by Disease 
             13.7.4. by End-user 
             13.7.5. by Country/Sub-region

14. Latin America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
     14.1. Introduction
             14.1.1. Key Findings
     14.2. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027
             14.2.1. Retroviruses 
             14.2.2. Adenoviruses 
             14.2.3. Adeno-associated Viruses
             14.2.4. Plasmid DNA
             14.2.5. Others
     14.3. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027
             14.3.1. Gene Therapy 
             14.3.2. Vaccinology
             14.3.3. Others 
     14.4. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027
             14.4.1. Genetic Disorders
             14.4.2. Cancer 
             14.4.3. Infectious Disease 
             14.4.4. Others
     14.5. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027
             14.5.1. Biotech Companies
             14.5.2. Research Institutes
     14.6. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027
             14.6.1. Brazil
             14.6.2. Mexico
             14.6.3. Rest of Latin America
     14.7. Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis 
             14.7.1. by Type 
             14.7.2. by Application 
             14.7.3. by Disease 
             14.7.4. by End-user 
             14.7.5. by Country/Sub-region

15. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
     15.1. Introduction
             15.1.1. Key Findings
     15.2. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027
             15.2.1. Retroviruses 
             15.2.2. Adenoviruses 
             15.2.3. Adeno-associated Viruses
             15.2.4. Plasmid DNA
             15.2.5. Others
     15.3. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027
             15.3.1. Gene Therapy 
             15.3.2. Vaccinology
             15.3.3. Others 
     15.4. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027
             15.4.1. Genetic Disorders
             15.4.2. Cancer 
             15.4.3. Infectious Disease 
             15.4.4. Others
     15.5. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027
             15.5.1. Biotech Companies
             15.5.2. Research Institutes
     15.6. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027
             15.6.1. GCC Countries
             15.6.2. South Africa
             15.6.3. Rest of Middle East & Africa
     15.7. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis 
             15.7.1. by Type 
             15.7.2. by Application 
             15.7.3. by Disease 
             15.7.4. by End-user 
             15.7.5. by Country/Sub-region

16. Competition Landscape
     16.1. Market Player – Competition Matrix (by Tier and Size of companies)
     16.2. Company Profiles
             16.2.1. Lonza
                        16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                        16.2.1.2. Product Portfolio
                        16.2.1.3. SWOT Analysis
                        16.2.1.4. Financial Overview
                        16.2.1.5. Strategic Overview
             16.2.2. Catapult
                        16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                        16.2.2.2. Product Portfolio
                        16.2.2.3. SWOT Analysis
                        16.2.2.4. Financial Overview
                        16.2.2.5. Strategic Overview
             16.2.3. uniQure N.V.
                        16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                        16.2.3.2. Product Portfolio
                        16.2.3.3. SWOT Analysis
                        16.2.3.4. Financial Overview
                        16.2.3.5. Strategic Overview
             16.2.4. FUJIFILM Diosynth Biotechnologies
                        16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                        16.2.4.2. Product Portfolio
                        16.2.4.3. SWOT Analysis
                        16.2.4.4. Financial Overview
                        16.2.4.5. Strategic Overview
             16.2.5. Kaneka Eurogentec S.A.
                        16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                        16.2.5.2. Product Portfolio
                        16.2.5.3. SWOT Analysis
                        16.2.5.4. Financial Overview
                        16.2.5.5. Strategic Overview
             16.2.6. Oxford Biomedica
                        16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                        16.2.6.2. Product Portfolio
                        16.2.6.3. SWOT Analysis
                        16.2.6.4. Financial Overview
                        16.2.6.5. Strategic Overview
             16.2.7. Spark Therapeutics, Inc.
                        16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                        16.2.7.2. Product Portfolio
                        16.2.7.3. SWOT Analysis
                        16.2.7.4. Financial Overview
                        16.2.7.5. Strategic Overview
             16.2.8. Cobrabiologics
                        16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                        16.2.8.2. Product Portfolio
                        16.2.8.3. SWOT Analysis
                        16.2.8.4. Financial Overview
                        16.2.8.5. Strategic Overview
             16.2.9. Merck kGA 
                        16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                        16.2.9.2. Product Portfolio
                        16.2.9.3. SWOT Analysis
                        16.2.9.4. Financial Overview
                        16.2.9.5. Strategic Overview

List of Tables

Table 01: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
Table 02: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
Table 03: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
Table 04: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 05: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Region, 2017?2027
Table 06: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country, 2017?2027
Table 07: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
Table 08: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
Table 09: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
Table 10: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 11: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 12: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
Table 13: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
Table 14: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
Table 15: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 16: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 17: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
Table 18: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
Table 19: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
Table 20: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 21: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 22: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
Table 23: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
Table 24: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
Table 25: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 26: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 27: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
Table 28: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
Table 29: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
Table 30: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

List of Figures

Figure 01: Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 02: Viral Vector & Plasmid DNA Manufacturing Market Value, by Type, 2018(A) 
Figure 03: Viral Vector & Plasmid DNA Manufacturing Market Snapshot
Figure 04: Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type
Figure 05: Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application
Figure 06: Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease
Figure 07: Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user
Figure 08: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017?2027
Figure 09: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type (2018)
Figure 10: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user (2018)
Figure 11: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Region (2018)
Figure 12: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2018–2026
Figure 13: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
Figure 14: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Lentivirus, 2017?2027
Figure 15: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Adenovirus, 2017?2027
Figure 16: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Adeno-Associated Virus (AAV), 2017?2027
Figure 17: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Plasmid DNA, 2017?2027
Figure 18: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027
Figure 19: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2018–2026
Figure 20: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
Figure 21: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gene Therapy, 2017?2027
Figure 22: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Vaccinology, 2017?2027
Figure 23: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027
Figure 24: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027
Figure 25: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
Figure 26: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Genetic Disorders, 2017?2027
Figure 27: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cancer, 2017?2027
Figure 28: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Infectious Disease, 2017?2027
Figure 29: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027
Figure 30: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2018–2026
Figure 31: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
Figure 32: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biotech Companies
Figure 33: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Research Institutes 
Figure 34: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Region, for 2018 and 2027 
Figure 35: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Region, 2018–2026
Figure 36: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027
Figure 37: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country, 2019–2027
Figure 38: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country, 2018 and 2027
Figure 39: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027
Figure 40: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
Figure 41: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027
Figure 42: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
Figure 43: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027
Figure 44: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
Figure 45: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027
Figure 46: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
Figure 47: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027
Figure 48: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share (%), by Country/Sub-region, 2018 and 2027
Figure 49: Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 50: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027
Figure 51: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
Figure 52: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027
Figure 53: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
Figure 54: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027
Figure 55: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
Figure 56: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027
Figure 57: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
Figure 58: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027
Figure 59: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 60: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-region, for 2018 and 2027
Figure 61: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027
Figure 62: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
Figure 63: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027
Figure 64: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
Figure 65: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027
Figure 66: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
Figure 67: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027
Figure 68: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
Figure 69: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027
Figure 70: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 71: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 72: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027
Figure 73: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
Figure 74: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027
Figure 75: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
Figure 76: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027
Figure 77: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
Figure 78: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027
Figure 79: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
Figure 80: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027
Figure 81: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-Region, 2019–2027
Figure 82: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-Region, 2018 and 2027
Figure 83: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027
Figure 84: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
Figure 85: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027
Figure 86: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
Figure 87: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027
Figure 88: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
Figure 89: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027
Figure 90: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

.